Skip to content
Clinical Trials – home
PortugalBack to Portugal

Clinical trials in Touguinho – page 36

697 clinical trials in Touguinho, Portugal. Every trial is listed in the EU Clinical Trials Register and updated daily.

PortugalOur site in PortugalEnsaios-Clinicos.pt(opens in a new tab)
Touguinho at a glance
697
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

697 trials in Touguinho

Open in trial search

Study on the Effects and Safety of GLM101 for Patients with PMM2-CDG

Registered drug
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Glycomine Inc.

Study on Macitentan for Children with Pulmonary Arterial Hypertension

InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:0–17 years · Healthy volunteers
  • Substances:Macitentan
  • Sponsor:Actelion Pharmaceuticals Ltd.

Study on the Bioavailability of Nilotinib in Healthy Individuals with Chronic Myelogenous Leukemia (CML)

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · Healthy volunteers
  • Substances:Nilotinib
  • Sponsor:Bluepharma Industria Farmaceutica S.A.

Study Comparing Axatilimab to Best Available Therapy for Patients with Chronic Graft-Versus-Host Disease After Two or More Treatments

InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Axatilimab
  • Sponsor:Incyte Corp.

Hidradenitis

Not recruiting

Study on the Effects of Remibrutinib for Adults with Moderate to Severe Hidradenitis Suppurativa

Registered drug
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

Study on the Effects of Bexicaserin for Treating Seizures in Children and Adults with Dravet Syndrome

Investigational
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Bexicaserin hydrochloride
  • Sponsor:Longboard Pharmaceuticals Inc.

Systemic scleroderma

Not recruiting

Study on the Effectiveness and Safety of Efgartigimod PH20 SC for Adults with Systemic Sclerosis

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Multiple sclerosis

Not recruiting

Study on the Effectiveness and Safety of Frexalimab and Teriflunomide for Adults with Relapsing Multiple Sclerosis

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Ocular myasthenia

Not recruiting

Study on the Effectiveness and Safety of Efgartigimod in Adults with Ocular Myasthenia Gravis

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Study Comparing Acasunlimab and Pembrolizumab with Docetaxel for Patients with Metastatic Non-Small Cell Lung Cancer After Previous Treatments

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Acasunlimab
  • Sponsor:Genmab A/S

Neurodermatitis

Not recruiting

Study on Dupilumab for Itch Relief in Adults with Lichen Simplex Chronicus (Neurodermatitis)

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Dupilumab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

HIV infection

Not recruiting

Study of Weekly Oral GS-1720 and GS-4182 for Untreated HIV-1 Patients

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Bictegravir
  • Sponsor:Gilead Sciences Inc.

Other cities in Portugal

The busiest research cities in the country

All 48 cities in Portugal

Clinical research in Touguinho

What the registry says about research in the country

01 Mental Health Research

Clinical investigations focusing on Major Depressive Disorder (MDD) with concurrent insomnia symptoms, exploring innovative therapeutic approaches through combination treatments.

  • Depression Management
  • Sleep Disorders
  • Combination Therapy

The research evaluates the effectiveness of seltorexant as an adjunctive therapy alongside traditional antidepressants, specifically targeting patients who haven't responded adequately to standard SSRI/SNRI treatments.

02 Treatment Resistance Studies

Innovative research examining new therapeutic options for patients with treatment-resistant depression, focusing on dual-action approaches that address both mood and sleep disturbances.

  • Medication Augmentation
  • Symptom Management
  • Long-term Outcomes

The studies aim to evaluate both immediate therapeutic benefits and long-term effectiveness in preventing symptom relapse.

03 Sleep-Depression Interface

Groundbreaking research exploring the connection between sleep disorders and major depression, investigating integrated treatment approaches for better patient outcomes.

  • Sleep Quality
  • Mood Regulation
  • Combined Symptoms

These trials specifically target the dual presentation of depression and insomnia, addressing multiple symptoms through innovative pharmacological interventions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.